|
|
||||||||
Articles |
Endocrine Section, Washington Hospital Center, Medlantic Research Institute, George Washington University Medical Center, Washington, DC, USA.
We have studied the effects of immunoglobulin G from Graves' disease patients on phospholipase A2 (PLA2) and C(PLC) systems in FRTL-5 and human thyroid cells. Immunoglobulin G (IgG) from Graves' disease patients stimulated arachidonic acid (AA) release in a time- and dose-dependent manner. In FRTL-5 thyroid cells, removal of external calcium had no significant effect on the IgG (20 micrograms/ml)-induced AA release in FRTL-5 thyroid cells. U-73122 (3 mumol/l), a PLC inhibitor, and quinacrine (100 mumol/l) but not U-26384 (5 mumol/l), PLA2 inhibitors, blocked the IgG-induced (20 micrograms/ml) AA release in FRTL-5 thyroid cells. Immunoglobulin G (100 micrograms/ml) also stimulated accumulation of inositol-1,4,5-triphosphate (IP3) in a time- and dose-dependent (20-300 micrograms/ml) manner in FRTL-5 cells. Immunoglobulin G from Graves' disease patients induced a significant increase of IP3 production (p = 0.01) compared to IgG from normal subjects. Removal of external calcium had no significant effect on the IgG-induced IP3 production. The PLC inhibitor U-73122 completely blocked IgG-induced IP3 production from FRTL-5 thyroid cells. Also, in human thyroid cells, IgG from Graves' disease patients induced a significant increase of AA release (p = 0.001) and IP3 production (p = 0.004) compared to the IgG from normal subjects. These data indicate that IgG from Graves' disease patients induced PLA2 activity that was PLC dependent, a pattern referred to as sequential activation. Our studies suggest that IgG from Graves' disease patients activates PLA2 and PLC systems in FRTL-5 and human thyroid cells. These signal transduction pathways could be involved in the pathogenesis of Graves' disease and future studies are warranted to investigate this area.
This article has been cited by other articles:
![]() |
R. Han and T. J. Smith Cytoplasmic Prostaglandin E2 Synthase Is Dominantly Expressed in Cultured KAT-50 Thyrocytes, Cells That Express Constitutive Prostaglandin-endoperoxide H Synthase-2. BASIS FOR LOW PROSTAGLANDIN E2 PRODUCTION J. Biol. Chem., September 20, 2002; 277(39): 36897 - 36903. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. G. Gianoukakis, H. J. Cao, T. A. Jennings, and T. J. Smith Prostaglandin endoperoxide H synthase expression in human thyroid epithelial cells Am J Physiol Cell Physiol, March 1, 2001; 280(3): C701 - C708. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Di Cerbo, R. Di Paola, C. Menzaghi, V. De Filippis, K. Tahara, D. Corda, and L. D. Kohn Graves' Immunoglobulins Activate Phospholipase A2 by Recognizing Specific Epitopes on Thyrotropin Receptor J. Clin. Endocrinol. Metab., September 1, 1999; 84(9): 3283 - 3292. [Abstract] [Full Text] |
||||
![]() |
T. J. Smith, T. A. Jennings, D. Sciaky, and H. J. Cao Prostaglandin-endoperoxide H Synthase-2 Expression in Human Thyroid Epithelium. EVIDENCE FOR CONSTITUTIVE EXPRESSION IN VIVO AND IN CULTURED KAT-50 CELLS J. Biol. Chem., May 28, 1999; 274(22): 15622 - 15632. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |